FBXL4 and prostate cancer: The relatively low frequency of FBXL4 genomic region loss in primary tumours and its significant increase in frequency in metastatic samples (p = 0.0003, Supplementary Table 1) further supports the hypothesis that FBXL4 is a gene that suppresses prostate cancer metastatic progression.